Fighting Counterfeit Drugs with Pharmaceutical Serialization

|

article image
In the fight to eliminate the multi-billion dollar counterfeit drug problem, the Drug Supply Chain Security Act (DSCSA) will require pharmaceutical manufacturers to serialize their products by November 2017. Repackagers must serialize products by November 2018. To maximize profitability, you need to fight drug counterfeiting and improve operational efficiency by capturing serialized data in real-time. By providing your team with the tools to capture traceability and aggregated data, you can optimize many areas of your business—from production to the warehouse, and beyond.

Spotlight

Pro Pharmaceuticals Group (Australia)

Pro Pharmaceuticals Group, a specialty pharmaceutical company, focuses on sourcing and licencing products to meet medical needs. Over the last 3 years we have grown our customer base, products and suppliers. Pro Pharmaceuticals Group is a privately owned company was founded in 2015 and is headquartered in Melbourne, Australia.

OTHER ARTICLES

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | February 11, 2020

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

Five Ways to Manage Your Trial Effectively in a Fast-Changing Global Environment

Article | February 11, 2020

Over the past half-century, clinical trials have grown increasingly complex. A flood of new data from novel sources combined with more elaborate study designs and tougher regulatory standards have lengthened timelines and hiked costs, contributing to a steady decline of efficiency. It all adds up: Nearly half of all drug launches underperform revenue expectations. And if that isn’t enough, the outbreak of COVID-19 worldwide is having an effect on how life sciences companies operate their businesses, including how clinical trials are conducted. Most clinical trial research organizations have tried to adapt by tweaking a platform here, adding a new app there, but this has only yielded patchwork systems of sites, spreadsheets and dashboards that further burden the process.

Read More

How Pharma Companies Can Scale Up Their Knowledge Discovery with Semantic Similarity Search

Article | February 11, 2020

Pharma has deep roots in human history with centuries of folk pharmaceutical knowledge offering a hit-and-miss range of natural remedies. But the industry as we know it today actually emerged in the second half of the 19th century when the world’s first factory for the sole production of medicines was found. By the late 19th and early 20th century, some chemical companies had already begun using research labs to explore the medical applications for their products. Fast forward to today and the pharmaceutical sector is a global trillion-dollar industry. However, to ensure the safety and efficacy of drugs, the process of drug discovery and development is under extensive scrutiny and control on both national and global levels.

Read More

Clinical Development Risks and Issues in a COVID-19 World

Article | February 11, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

Spotlight

Pro Pharmaceuticals Group (Australia)

Pro Pharmaceuticals Group, a specialty pharmaceutical company, focuses on sourcing and licencing products to meet medical needs. Over the last 3 years we have grown our customer base, products and suppliers. Pro Pharmaceuticals Group is a privately owned company was founded in 2015 and is headquartered in Melbourne, Australia.

Events